Kirti Desai, CPA, Tevogen’s (TVGN) CFO, commented, “The company is in a unique position as it relates to reporting intangible assets on our balance sheet. Tevogen has multiple granted patents, which were developed internally, and as per US GAAP rules, these internally developed intangible assets are not reported on the balance sheet as they do not have an acquisition price. This is significantly different than IP obtained through acquisition which can be capitalized as a noncurrent asset on the balance sheet and subsequently amortized like an intangible asset.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVGN:
- Tevogen leverages Microsoft partnership to deliver target identification for HPV
- Tevogen regains compliance with Nasdaq
- Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz
- Tevogen provides more guidance on ExacTcell technology
- McDonald’s down after outbreak, Starbucks slides after warning: Morning Buzz